SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS (SPMS)
Clinical trials for SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS (SPMS) explained in plain language.
Never miss a new study
Get alerted when new SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS (SPMS) trials appear
Sign up with your email to follow new studies for SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS (SPMS), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New cell therapy trial aims to halt debilitating MS progression
Disease control Recruiting nowThis early-stage clinical trial is testing an experimental cell therapy called TRX319 in adults with progressive forms of multiple sclerosis (MS). The main goals are to check if the treatment is safe, find the best dose, and see if it can slow or stop the worsening of MS symptoms…
Matched conditions: SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS (SPMS)
Phase: PHASE1, PHASE2 • Sponsor: Tr1X, Inc. • Aim: Disease control
Last updated Apr 03, 2026 21:11 UTC
-
Can a cancer drug help MS patients think and move better?
Disease control Recruiting nowThis study is testing whether the drug rituximab can improve thinking skills and hand function in people with advanced secondary progressive multiple sclerosis (SPMS). Researchers will compare 46 participants with significant disability—half receiving rituximab and half receiving…
Matched conditions: SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS (SPMS)
Phase: PHASE2 • Sponsor: Cairo University • Aim: Disease control
Last updated Apr 03, 2026 14:43 UTC
-
Major trial aims to halt MS progression in its tracks
Disease control Recruiting nowThis large, late-stage study is testing whether an investigational drug called remibrutinib can slow or stop the worsening of disability in people with secondary progressive multiple sclerosis (SPMS). About 1,275 participants will be randomly assigned to receive either the drug o…
Matched conditions: SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS (SPMS)
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Mar 16, 2026 15:27 UTC